Fermented Oyster Extract Improves Linear Growth in Children with Idiopathic Short Stature: A Randomized, Double-Blind, Placebo-Controlled Trial
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- ESCIKCIScopus
- 저널 순위
- JCR Q3Scopus Q2KCI Q4
- 저널
- PREVENTIVE NUTRITION AND FOOD SCIENCE31(2) · #ART003329000 · 2026
- 피인용
- Scopus 0KCI 0
- FWCI (Scopus)
- 0
- JCR IF
- JCR 2024 2.5
- ISSN
- 2287-1098
저자
- Nagahawatta, D. P.제1저자Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2B7, Canada
- Yang, FengqiDepartment of Marine Life Sciences, Jeju National University, Jeju 63243, Korea
- Liyanage, N. M.Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2B7, Canada
- Kyoung-Min, RheuMarine Bioprocess Co., Ltd., Busan 46048, Korea
- Bae-Jin, LeeMarine Bioprocess Co., Ltd., Busan 46048, Korea
- 김기봉교신저자Department of Korean Pediatrics, School of Korean Medicine, Pusan National University, Yangsan 50612, Korea
- You-Jin, Jeon교신저자Department of Marine Life Sciences, Jeju National University, Jeju 63243, Korea
초록
This randomized, double-blind, placebo-controlled clinical trial evaluated the efficacy and safety of fermentedoyster extract (FGO) as a functional food ingredient for promoting growth in children with idiopathic short stature (ISS). In total, 80 children aged 6-9 years with height below the 25th percentile for age and gender per the Korean NationalGrowth Charts, 2017, were included. They were randomly assigned to receive either 500 mg/d FGO or a matched placebofor 24 weeks. The primary outcome was a change in height while standing; secondary outcomes included growth rate,height standard deviation score (height-SDS), bone age (BA), and levels of growth-related hormones and bone metabolismmarkers. In the intention-to-treat analysis, mean height gain at 24 weeks was 3.22±0.71 and 2.38±0.74 cm in theFGO and placebo groups (P<0.001). Growth rate, height-SDS, BA, serum insulin-like growth factor-1, and urinary deoxypyridinolineincreased significantly in the FGO group compared with the placebo group (P<0.05). In contrast, growthhormone and insulin-like growth factor-binding protein-3 levels did not vary between groups. No serious adverse eventsor clinically meaningful laboratory abnormalities were observed; however, two events of mild rash, possibly related toFGO, led to one drop-out. These findings suggest that standardized FGO may safely augment linear growth and bone metabolismin children with ISS. This product could be developed as a marine-derived functional food for pediatric growthsupport, although more long-term and multicenter studies are warranted to confirm the generalizability of these effectsand FGO durability.
키워드
body heightclinical trialfermentationoystersrandomized controlled trial
식별자
- Scopus EID
- 2-s2.0-105037042041
- KCI
- ART003329000



로그인
연구물 목록으로